Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

Sun Yat-sen University60 enrolled

Overview

Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Allogene MSCs Transplantation Chronic Liver Diseases Patients Peripheral Vein

Eligibility

Sex: ALLMin age: 15 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease. 2. age: 15-65 years old. Exclusion Criteria: 1. pregnant women and women in lactation. 2. other systems and organs disfunction 3. space-occupying lesion were found in liver. 4. concurrent infection with HIV and other immunodeficiency diseases. 5. DIC and active bleeding were confirmed.

Locations (1)

Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein.

Time frame: 1-8 weeks after transplantation

Secondary Outcomes

Long-term follow-up of Allogene MSCs transplantation through peripheral vein.

Time frame: 3-60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.